重组人血小板生成素联合环孢素并护理干预治疗特发性血小板减少性紫癜60例临床评价  

Recombinant Human Thrombopoietin Combined with Cyclosporin A and Nursing for Reducing Idiopathic Thrombocytopenic Purpura in 60 Cases

作　　者：何秋仙[1] 周晓红[1] 

机构地区：[1]陕西省人民医院,陕西西安710068

出　　处：《中国药业》2015年第23期33-35,共3页China Pharmaceuticals

摘　　要：目的探讨重组人血小板生成素联合环孢素治疗特发性血小板减少性紫癜的疗效。方法将特发性血小板减少性紫癜患者120例随机分为观察组和对照组,各60例。对照组给予环孢素口服溶液,观察组在对照组基础上联用重组人血小板生成素。两组患者采用相同的护理干预,包括心理、皮肤出血、消化道出血和颅内出血护理。结果治疗后,观察组总有效率为88.33%,高于对照组的68.33%(P<0.05)。与治疗前相比,治疗后两组患者血小板计数均明显增加(P<0.05),治疗后10 d,观察组血小板计数明显高于对照组(P<0.05)。对照组血红蛋白水平无明显变化(P>0.05),观察组较治疗前和对照组均显著升高(P<0.05)。两组患者治疗前后白细胞水平均无显著变化(P>0.05)。观察组不良反应发生率为11.67%,与对照组的13.33%相当(P>0.05)。结论重组血小板生成素联合环孢素并护理干预治疗特发性血小板减少性紫癜患者临床疗效较好,患者血小板计数和血红蛋白明显增加,且临床不良反应较小,安全性较高。Objective To study the efficacy of recombinant human thrombopoietin combined with cyclosporin A and nursing in treating idiopathic thrombocytopenic purpura. Methods 120 cases of patients with idiopathic thrombocytopenic purpura from June 2013 to December 2014 were randomly divided into observation group and control group,60 cases in each group. The control group was given Cyclosporin A Oral Solution,on this basis the observation group was given Recombinant Human Thrombopoietin. The two groups received the same nursing, including psychological nursing, skin bleeding nursing and intracranial hemorrhage of gastrointestinal bleeding. Results After treatment,the total effective rate of the observation group was 88. 33%,which was significantly higher than 68. 33% of the control group（ P 〈 0. 05）; compared with before treatment, the platelet count in the two groups were significantly increased（ P 〈 0. 05）; 10 d after treatment,the platelet count of the observation group was obviously higher than that of the control group（ P 〈 0. 05）; the Hb level of the control group had no significant change（ P 〉 0. 05）, while the observation group was significantly higher than before treatment and the control group（ P 〈 0. 05）; the WBC levels of the two groups had no significant changes（ P 〉 0. 05）; the incidence rate of the adverse reactions in the observation group was 11. 67%,which had no significant difference with 13. 33% of the control group（ P 〉 0. 05）.Conclusion Recombinant human thrombopoietin（ rh TPO） combined with cyclosporin A treatment of idiopathic thrombocytopenic purpura patients with good clinical efficacy,combined with nursing of patients for treatment,curative effect is better,the platelet count was significantly increased and less adverse reactions and high security. But whether the drug can be used for a long time,it needs to be further studied.

关 键 词：重组人血小板生成素 环孢素 特发性血小板减少性紫癜 临床疗效 安全性 

分 类 号：R969.4[医药卫生—药理学] R977.6[医药卫生—药学]